Investigational drug · Phase 2
ART5803
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE), Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease, Autoimmune Encephalitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ART5803"
First trial start
2026
May 15, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ART5803", any sponsor or status.
Conditions studied
As listed on its trial records.
- Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)
- Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease
- Autoimmune Encephalitis
Largest trials
Live from ClinicalTrials.gov: studies naming "ART5803" as an intervention, largest first.
Arialys TherapeuticsIndustry
NCT06575153 · 64 participants · Start Sep 19, 2024 · Primary completion Sep 11, 2025
Drug: ART5803 · For: Autoimmune Encephalitis
Sites: Melbourne, Australia
Arialys Australia Pty LtdIndustry
NCT07093333 · 30 participants (planned) · Start May 15, 2026 · Primary completion Nov 30, 2027
Drug: ART5803; ART5803-Cohort D · For: Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE); Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease; Autoimmune Encephalitis
Sites: Seoul, South Korea
Arialys TherapeuticsIndustry
NCT06753955 · 7 participants · Start Feb 25, 2025 · Primary completion Jul 2, 2025
Drug: ART5803; Intravenous immunoglobulin (IVIG) · For: Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody; Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder); Autoimmune Encephalitis
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis.
Kanno A, Kito T, Maeda M, et al. · Nat Commun 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.